Vertex Pharmaceuticals (NASDAQ:VRTX) Price Target Raised to $575.00

Vertex Pharmaceuticals (NASDAQ:VRTX) had its target price lifted by TD Cowen from $550.00 to $575.00 in a research note issued to investors on Tuesday morning,Benzinga reports. The firm currently has a buy rating on the pharmaceutical company’s stock.

VRTX has been the subject of a number of other reports. UBS Group upped their target price on Vertex Pharmaceuticals from $585.00 to $615.00 and gave the company a “buy” rating in a research report on Monday, September 28th. Canaccord Genuity Group raised their price target on Vertex Pharmaceuticals from $436.00 to $442.00 and gave the stock a “hold” rating in a research report on Tuesday, August 4th. Truist Financial boosted their price target on Vertex Pharmaceuticals from $560.00 to $565.00 and gave the company a “buy” rating in a research note on Wednesday, August 5th. Sanford C. Bernstein raised shares of Vertex Pharmaceuticals to a “strong-buy” rating in a research report on Wednesday, July 29th. Finally, Leerink Partners started coverage on shares of Vertex Pharmaceuticals in a research report on Monday, September 21st. They set an “outperform” rating and a $594.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, twenty-five have given a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $596.44.

Vertex Pharmaceuticals Stock Down 1.2%

NASDAQ VRTX opened at $542.50 on Tuesday. The company has a current ratio of 2.34, a quick ratio of 2.74 and a debt-to-equity ratio of 0.17. Vertex Pharmaceuticals has a 1-year low of $406.67 and a 1-year high of $568.67. The company has a 50 day moving average of $522.81 and a 200-day moving average of $481.42. The company has a market cap of $137.69 billion, a price-to-earnings ratio of 34.91, a PEG ratio of 2.84 and a beta of 0.28.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings results on Monday, November 2nd. The pharmaceutical company reported $4.76 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.82 by ($0.06). The company had revenue of $3.44 billion during the quarter, compared to the consensus estimate of $3.42 billion. Vertex Pharmaceuticals had a net margin of 30.70% and a return on equity of 21.98%. The company’s quarterly revenue was up 11.8% on a year-over-year basis. During the same quarter last year, the firm posted $4.80 earnings per share. On average, equities research analysts expect that Vertex Pharmaceuticals will post 16.50 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Vertex Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. BlackRock Inc. bought a new stake in Vertex Pharmaceuticals in the second quarter worth approximately $11,975,849,000. State Street Corp boosted its holdings in shares of Vertex Pharmaceuticals by 1.2% during the 2nd quarter. State Street Corp now owns 11,871,459 shares of the pharmaceutical company’s stock worth $5,896,910,000 after buying an additional 141,320 shares in the last quarter. Wellington Management Group LLP boosted its holdings in shares of Vertex Pharmaceuticals by 1.1% during the 2nd quarter. Wellington Management Group LLP now owns 3,247,658 shares of the pharmaceutical company’s stock worth $1,613,209,000 after buying an additional 35,069 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of Vertex Pharmaceuticals by 1.0% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,086,683 shares of the pharmaceutical company’s stock worth $1,533,248,000 after buying an additional 29,287 shares during the period. Finally, Bank of America Corp DE acquired a new stake in shares of Vertex Pharmaceuticals during the 2nd quarter worth approximately $1,509,651,000. 90.96% of the stock is currently owned by institutional investors.

More Vertex Pharmaceuticals News

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Vertex reported third-quarter revenue of $3.44 billion, up about 12% year over year, and raised its 2026 revenue forecast to $13.15 billion–$13.25 billion. Growth was supported by its cystic fibrosis business and newer products, including CASGEVY. The company also faces a key November 30 FDA decision date for povetacicept in IgA nephropathy. Q3 earnings call highlights
• Positive Sentiment: Multiple analysts raised Vertex price targets or reiterated Buy/Overweight ratings, including Barclays, TD Cowen, JPMorgan, Goldman Sachs, Stifel, Cantor Fitzgerald, RBC, UBS, Wells Fargo, and Scotiabank. The broad positive analyst tone points to confidence in the company’s outlook. Barclays price-target increase
• Positive Sentiment: A longer-term bullish view cited Vertex’s strong position in cystic fibrosis and its gradual expansion into other treatments as reasons it could remain an attractive biotech stock. Long-term outlook
• Neutral Sentiment: Third-quarter revenue exceeded analyst estimates, but earnings per share of $4.76 came in slightly below the $4.82 consensus—an offset to the encouraging sales and guidance update.
• Negative Sentiment: Morgan Stanley lowered its expectations for Vertex’s stock price, offering a counterpoint to the wave of target increases. Morgan Stanley outlook

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated is a global biotechnology company focused on developing and commercializing medicines for serious diseases. Founded in 1989 and headquartered in Boston, Massachusetts, the company applies expertise in the science of human disease to discover therapies that address significant unmet medical needs.

Vertex is best known for its cystic fibrosis portfolio, which includes Kalydeco, Orkambi, Symdeko/Symkevi, and Trikafta/Kaftrio. These medicines target the underlying cause of cystic fibrosis for patients with specific mutations in the CFTR gene.